Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Clinical trial NCT03702231 · COMPLETED

Trial details

NCT number: NCT03702231
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Safety and Tolerability Compare SHINGRIX Vaccine Response Rates Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Start date: 2018-12-07
Primary completion: 2020-09-09
Enrollment: 116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.